CASP3 and rheumatoid arthritis: In 2016, Gao reported that Pristimerin (15) (0.4, 0.8 mg/kg, i.p.)significantly improved the RA symptoms of AIA rats, and further investigations revealed that Pristimerin (0.75–3 μM) can induce apoptosis of rFLS (AIA) via regulation of expressions of Bcl-2, Bax and Caspase-3 [73].